

April 2024

Notes from the U.S. Growth Equity Desk



Michael Li, Ph.D.

Sr. Portfolio Manager



Henry He, CFA

Portfolio Manager




Kevin Lewis, CFA

Sr. Client Portfolio Manager

Market Highlights


- U.S. stock indices hit record highs in the first quarter of 2024, propelled by optimism around the economy and interest rates. Solid corporate earnings growth also helped the S&P 500 Index gain more than 10%.
- In such a strong period for stocks, the Health Care sector registered gains but trailed the broad market. Within the Russell 3000 Health Care Index, every industry rose.
- Pharmaceuticals stocks performed best, led by obesity drug makers. Health Care Providers and Services stocks generally gained the least because of worries about Medicare reimbursement rates, regulatory oversight and business disruption from a cyberattack.

Health Care Sector Performance



Data as of 3/31/2024. Source: FactSet.

Health Care Industry Performance Last Quarter



Data from 1/1/2024 to 3/31/2024. Source: FactSet.

Annualized performance in USD.

Past performance is not a guarantee of future results.

Uptick in Surgical Procedures Benefit Medical Device Companies

In early 2024, several prominent medical device companies issued positive earnings results and outlooks.¹

That contrasts with earnings and outlooks resulting from a series of challenges going back to 2020, when elective surgical procedures decreased thanks to the impacts of the coronavirus and the Great Resignation on hospital staffing. Medical device companies have also faced supply chain disruptions and rising inflation, weighing on profits. And their stock prices have been negatively impacted by investor fears that obesity drugs would lead to fewer medical device procedures.

But over the course of the last year, many of these factors have turned back in the companies' favor. Inflation woes and supply chain issues eased. And health care employment issues largely resolved by mid-2023.²

The effect of obesity drugs on procedures is more nuanced. For example, in its fourth-quarter 2023 earnings report, Intuitive Surgical said that the number of bariatric surgeries performed with its devices had grown, but at a slower rate than in the past.³ This is attributable to patients having opted for drugs to treat obesity. Meanwhile, Stryker has highlighted the benefit that obesity drugs will have on orthopedic surgery volumes. In the short run, rapid weight loss will help ineligible people become eligible for surgeries sooner. In the long run, large-scale weight loss will likely result in more orthopedic surgeries as people increase their activity levels.

Aging Population Should Support Medical Device Firms

Many medical device companies are aligned with enduring trends driving procedure growth over time. Specifically, an aging global population is leading to the need for more joint replacement surgery. Age is the strongest predictor of the development and progression of osteoarthritis, one of the 10 most-disabling diseases in developed countries.

Joint replacement surgery (hip and knee replacement) is considered the most effective intervention for severe osteoarthritis and hip fractures. In Japan, approximately 60,000 total hip replacements and 82,000 total knee and partial knee replacements are performed annually, with these numbers expected to rise due to the nation's aging population.⁴

Stryker is an innovative medical device manufacturer whose MAKO robotics platform is the leader in knee procedures and is expanding to other orthopedic areas. The company has a strong management team that has consistently driven organic revenue growth faster than the industry. The company also has attractive high operating margins. Our analysis indicates Stryker's business is consistent with the social impact goals of new or innovative treatments for diseases, as well as access to medicines and services in developed and emerging markets.

¹ Reuters, "Intuitive Beats Estimates as Rebound in Surgeries Boost Demand for Its Robots," January 23, 2024.

² Molly Gamble, "The Great Resignation Is a Now Misleading Storyline for Hospitals: Analysis," Becker's Hospital Review, January 22, 2024.

³ Motley Fool Transcribing, "Intuitive Surgical (ISRG) Q4 2023 Earnings Call Transcript," January 23, 2024.

⁴ Stryker, Annual Review, 2019.

American Century ESG Trend Signals** are defined as follows:

Positive – The issuer's overall ESG profile or performance under a given pillar is improving over the last three years or that it is projected to improve (outlook).

Stable – The issuer's overall ESG profile or performance under a given pillar is neither improving nor worsening over the last three years.

Negative – The issuer's overall ESG profile or performance under a given pillar is deteriorating over the last three years or that is projected to worsen (outlook).

**Please note that the ESG Trend Signals apply to both an issuer's overall ESG quality rating and its performance under individual E, S and G pillars.

Sustainable Development Goals (SDGs) are a collection of 17 global goals set by the United Nations General Assembly. They were developed by a global team of industry and government leaders and adopted by all 193 member states, the SDGs include 17 goals and 169 attendant targets aimed at solving some of the world's most pressing problems by 2030. The goals include eradicating poverty, providing environmental resources, and achieving gender and income equality.

Many of American Century's investment strategies incorporate sustainability factors, using environmental, social, and/or governance (ESG) data, into their investment processes in addition to traditional financial analysis. However, when doing so, the portfolio managers may not consider sustainability-related factors with respect to every investment decision and, even when such factors are considered, they may conclude that other attributes of an investment outweigh sustainability factors when making decisions for the portfolio. The incorporation of sustainability factors may limit the investment opportunities available to a portfolio, and the portfolio may or may not outperform those investment strategies that do not incorporate sustainability factors. ESG data used by the portfolio managers often lacks standardization, consistency, and transparency, and for certain companies such data may not be available, complete, or accurate.

Past performance is no guarantee of future results.

The opinions expressed are those of the portfolio team and are no guarantee of the future performance of any American Century Investments portfolio. This information is for an educational purpose only and is not intended to serve as investment advice. References to specific securities are for illustrative purposes only, and are not intended as recommendations to purchase or sell securities. Opinions and estimates offered constitute our judgment and, along with other portfolio data, are subject to change without notice.

This information is not intended as a personalized recommendation or fiduciary advice and should not be relied upon for investment, accounting, legal or tax advice.

No offer of any security is made hereby. This material is provided for informational purposes only and does not constitute a recommendation of any investment strategy or product described herein. This material is directed to professional/institutional clients only and should not be relied upon by retail investors or the public. The content of this document has not been reviewed by any regulatory authority.

This promotion has been approved with limitations, in accordance with Section 21 of the Financial Services and Markets Act, by American Century Investment Management (UK) Limited, which is authorised and regulated by the Financial Conduct Authority. This promotion is directed at persons having professional experience of participating in unregulated schemes and units to which the communication relates are available only to such persons. Persons who do not have professional experience in participation in unregulated schemes should not rely on it.

American Century Investment Management (UK) Limited is registered in England and Wales. Registered number: 06520426. Registered office: 12 Henrietta Street, 4th Floor, London, WC2E 8LH.

American Century Investment Management (Asia Pacific), Limited currently holds Type 1 and Type 4 registrations from the Securities and Futures Commission ("SFC") and shall provide services only to Professional Investors as defined pursuant to the Securities and Futures Ordinance (Cap. 571) of Hong Kong. This presentation is intended solely for the Professional Investors and should not be used by persons not Professional Investors. American Century Investment Management, Inc. is not registered with the SFC.

The material in this document is published for general informational purposes only. This document is not designed for the purpose of providing financial product or investment advice. The information contained in this document does not take into account your particular investment objectives, financial situation or investment needs. You should seek personal financial product or investment advice and consider whether the information contained in this document is appropriate to your particular investment objectives, financial situation and investment needs before making an investment decision.

American Century Investment Management, Inc. (ACIM) is exempt from holding an AFSL under the Corporations Act 2011 (Cth) (Australian Corporations Act) in respect of the financial services it provides to "wholesale clients" for the purposes of the Australian Corporations Act and does not hold such a license. ACIM is regulated by the Securities and Exchange Commission (SEC) (CRD#105778/SEC#:801-8174) under the United States laws which differ from Australian laws. ACIM relies on ASIC relief provided for under Class Order [CO 03/1100] for U.S. SEC-regulated financial services providers in relation to the provision of financial services to Australian clients. The distributor and client services provider for the Fund is American Century Investment Management (AU) Pty Limited (American Century). American Century is an affiliate of ACIM and holds an AFSL (No: 518417) to provide general financial product advice to wholesale clients and will distribute the Fund in Australia.

American Century Investment Management, Inc. is not authorised by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin)). American Century Investments (EU) GmbH is registered by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin)).

American Century Investments ®

4500 Main Street
Kansas City, MO 64111
1-866-628-8826

330 Madison Avenue
New York, NY 10017
1-646-658-7700

3945 Freedom Circle
Santa Clara, CA 95054
1-866-628-8826

360 E 2nd Street
Los Angeles, CA 90071
1-866-628-8826

2 Ice House Street
Central, Hong Kong
+852 3405 2600

12 Henrietta Street
London, WC2E 8LH
+44 207 024 7080

1 Farrer Place
Sydney, NSW 2000
+61 2 88233403

Taunusanlage 8
60329 Frankfurt, Germany
+49 69 8088 5501